Mouse Von Willebrand Factor (vWF) ELISA Kit | vWF elisa kit

Mouse Von Willebrand Factor (vWF) ELISA Kit

Cat. Num. AAA2707503

• Gene Names: Vwf; VWD; F8VWF; AI551257; C630030D09; 6820430P06Rik; B130011O06Rik
• Reactivity: Mouse
• Synonyms: Von Willebrand Factor (vWF); Mouse Von Willebrand Factor (vWF) ELISA Kit; F8VWF; VWD; von Willebrand antigen 2; vWF elisa kit

• Reactivity: Mouse
• Specificity: This assay has high sensitivity and excellent specificity for detection of Von Willebrand Factor (vWF).; No significant cross-reactivity or interference between Von Willebrand Factor (vWF) and analogues was observed.
• Sequence Length: 2813

• Assay Type: Double-antibody Sandwich
• Samples: Plasma
• Detection Range: 25-1,600pg/mL
• Sensitivity: The minimum detectable dose of this kit is typically less than 11pg/mL
• Precision: Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Von Willebrand Factor (vWF) were tested 20 times on one plate, respectively.; Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Von Willebrand Factor (vWF) were tested on 3 different plates, 8 replicates in each plate.; CV(%) = SD/meanX100; Intra-Assay: CV<10%; Inter-Assay: CV<12%
• Preparation and Storage: The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.; To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Typical Testing Data/Standard Curve (for reference only)

Related Product Information for vWF elisa kit

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Von Willebrand Factor (vWF). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Von Willebrand Factor (vWF). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Von Willebrand Factor (vWF), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Von Willebrand Factor (vWF) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

NCBI and Uniprot Product Information

• NCBI GI #: 115511022
• NCBI GeneID: 22371
• NCBI Accession #: NP_035838.3
• NCBI GenBank Nucleotide #: NP_035838.3
• UniProt Accession #: Q8CIZ8
• NCBI Official Full Name: von Willebrand factor
• NCBI Official Synonym Full Names: Von Willebrand factor
• NCBI Official Symbol: Vwf
• NCBI Official Synonym Symbols: VWD; F8VWF; AI551257; C630030D09; 6820430P06Rik; B130011O06Rik
• NCBI Protein Information: von Willebrand factor
• UniProt Protein Name: von Willebrand factor
• Protein Family: von Willebrand factor
• UniProt Gene Name: Vwf
• UniProt Synonym Gene Names: vWF
• UniProt Entry Name: VWF_MOUSE

Uniprot Description

VWF: Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Defects in VWF are the cause of von Willebrand disease type 1 (VWD1). A common hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 1 is characterized by partial quantitative deficiency of circulating von Willebrand factor, that is otherwise structurally and functionally normal. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 2 (VWD2). A hemorrhagic disorder due to defects in von Willebrand factor protein and resulting in impaired platelet aggregation. Von Willebrand disease type 2 is characterized by qualitative deficiency and functional anomalies of von Willebrand factor. It is divided in different subtypes including 2A, 2B, 2M and 2N (Normandy variant). The mutant VWF protein in types 2A, 2B and 2M are defective in their platelet- dependent function, whereas the mutant protein in type 2N is defective in its ability to bind factor VIII. Clinical manifestations are mucocutaneous bleeding, such as epistaxis and menorrhagia, and prolonged bleeding after surgery or trauma. Defects in VWF are the cause of von Willebrand disease type 3 (VWD3). A severe hemorrhagic disorder due to a total or near total absence of von Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. Bleeding usually starts in infancy and can include epistaxis, recurrent mucocutaneous bleeding, excessive bleeding after minor trauma, and hemarthroses.

Protein type: Motility/polarity/chemotaxis; Cell adhesion; Secreted, signal peptide; Secreted; Extracellular matrix

Cellular Component: endoplasmic reticulum; external side of plasma membrane; extracellular matrix; extracellular region; proteinaceous extracellular matrix

Molecular Function: chaperone binding; collagen binding; glycoprotein binding; identical protein binding; immunoglobulin binding; integrin binding; protease binding; protein binding; protein homodimerization activity; protein N-terminus binding

Biological Process: blood coagulation; cell adhesion; cell-substrate adhesion; hemostasis; liver development; placenta development; platelet activation; protein homooligomerization